Vaxart, Inc. (VXRT) — 8-K Filings

8-K Filings (40)

• 8-K Filing — May 7, 2026
• 8-K Filing — Dec 29, 2025
• Vaxart, Inc. Files 8-K with Material Agreement — Nov 5, 2025 Risk: medium
  On November 4, 2025, Vaxart, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements
• Vaxart Files 8-K: Regulation FD Disclosure — Oct 10, 2025 Risk: medium
  Vaxart, Inc. filed an 8-K on October 10, 2025, reporting an event that occurred on October 8, 2025. The filing is a Regulation FD Disclosure, indicating it cont
• Vaxart, Inc. Files 8-K Report — Sep 19, 2025 Risk: low
  On September 18, 2025, Vaxart, Inc. filed an 8-K report detailing "Other Events." The filing does not disclose specific new events, financial figures, or materi
• Vaxart Files 8-K: Voting, Reg FD, Financials — Sep 8, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on September 8, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statement
• Vaxart, Inc. Files 8-K on Executive Changes and Disclosures — Sep 2, 2025 Risk: medium
  Vaxart, Inc. filed an 8-K on September 2, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain offic
• Vaxart, Inc. Files 8-K with Regulatory Updates — Aug 29, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on August 29, 2025, reporting events as of August 27, 2025. The filing includes information related to Regulation FD Disclosure, Other
• Vaxart, Inc. Files 8-K Current Report — Aug 21, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on August 21, 2025, reporting an event that occurred on August 20, 2025. The filing is a current report under Regulation FD and includ
• Vaxart, Inc. Files 8-K Report — Aug 15, 2025 Risk: low
  On August 14, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. Vaxart, Inc. is
• Vaxart, Inc. Files 8-K Report — Aug 6, 2025 Risk: low
  On August 5, 2025, Vaxart, Inc. filed an 8-K report detailing a material definitive agreement and other events. The company, previously known as Aviragen Therap
• Vaxart, Inc. Files 8-K Report — Jul 8, 2025 Risk: low
  On July 8, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new ma
• Vaxart Faces Delisting Concerns — Jul 2, 2025 Risk: high
  Vaxart, Inc. filed an 8-K on July 2, 2025, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates a po
• Vaxart, Inc. Files 8-K with Shareholder Votes and Disclosures — Jun 17, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders and providing a Regulation FD disclosure. The filing al
• Vaxart Files 8-K — Jun 11, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on June 11, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details a
• Vaxart Files 8-K: Shareholder Votes, Reg FD, Financials — Jun 2, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on June 2, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. Th
• Vaxart Files 8-K: Shareholder Votes, Reg FD, Financials — May 22, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on May 22, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements and
• Vaxart, Inc. Files 8-K Report — May 15, 2025 Risk: low
  On May 15, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or d
• Vaxart, Inc. Files 8-K on Financials and Operations — Mar 21, 2025 Risk: low
  Vaxart, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. Th
• Vaxart, Inc. Files 8-K Report — Mar 11, 2025 Risk: low
  On March 11, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. Vaxart, Inc. was formerly kno
• Vaxart, Inc. Files 8-K: Material Agreement and Other Events — Feb 24, 2025 Risk: medium
  On February 21, 2025, Vaxart, Inc. entered into a material definitive agreement. The company also reported other events on this date. Vaxart, Inc. is incorporat
• Vaxart, Inc. Files 8-K for Material Definitive Agreement — Feb 10, 2025 Risk: medium
  On February 7, 2025, Vaxart, Inc. entered into a Material Definitive Agreement. The company, previously known as Aviragen Therapeutics, Inc., Biota Pharmaceutic
• Vaxart Acquires Decoragen for $15M — Jan 28, 2025 Risk: medium
  Vaxart, Inc. announced on January 24, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Decoragen, Inc. for an aggregat
• Vaxart Files 8-K: Other Events & Exhibits — Jan 21, 2025 Risk: medium
  Vaxart, Inc. filed an 8-K on January 21, 2025, reporting an event that occurred on January 13, 2025. The filing pertains to "Other Events" and "Financial Statem
• Vaxart Faces Listing Rule Concerns — Dec 31, 2024 Risk: high
  Vaxart, Inc. filed an 8-K on December 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard, or the transfer of a
• Vaxart, Inc. Files 8-K for Material Definitive Agreement — Dec 27, 2024 Risk: medium
  On December 20, 2024, Vaxart, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any associ
• Vaxart, Inc. Files 8-K: Other Events & Exhibits — Dec 5, 2024 Risk: low
  Vaxart, Inc. filed an 8-K on December 5, 2024, reporting an event that occurred on December 2, 2024. The filing pertains to "Other Events" and "Financial Statem
• Vaxart Terminates Material Definitive Agreement — Oct 8, 2024 Risk: medium
  Vaxart, Inc. announced on October 8, 2024, the termination of a material definitive agreement. The filing does not specify the other party involved in the agree
• Vaxart, Inc. Files 8-K: Material Definitive Agreement — Sep 30, 2024 Risk: medium
  On September 27, 2024, Vaxart, Inc. entered into a Material Definitive Agreement. The filing also includes information on other events and financial statements
• Vaxart Faces Potential Delisting — Jul 5, 2024 Risk: high
  Vaxart, Inc. filed an 8-K on July 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates pote
• Vaxart, Inc. Files 8-K with Regulatory Updates — Jun 18, 2024 Risk: medium
  Vaxart, Inc. filed an 8-K on June 18, 2024, reporting an event on June 17, 2024. The filing is primarily a Regulation FD Disclosure and includes Financial State
• Vaxart, Inc. Files 8-K with Material Agreement — Jun 14, 2024 Risk: medium
  On June 13, 2024, Vaxart, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing but are indicated by th
• Vaxart Acquires Attenua for $10M — Jun 13, 2024 Risk: medium
  Vaxart, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of the privately held company, Moncef
• Vaxart, Inc. Files 8-K: Other Events & Exhibits — Apr 30, 2024 Risk: medium
  Vaxart, Inc. filed an 8-K on April 30, 2024, reporting other events and financial statements. The company, formerly known as Aviragen Therapeutics, Inc., Biota
• Vaxart, Inc. Files 8-K on Financials — Mar 14, 2024 Risk: low
  Vaxart, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Vaxart Appoints New CMO, Director; Discloses Officer Compensation — Mar 6, 2024 Risk: medium
  Vaxart, Inc. announced on March 4, 2024, the appointment of Dr. Sean Tucker as Chief Medical Officer and the election of Dr. Amy Peterson to its Board of Direct
• Vaxart Announces Leadership Changes and Executive Compensation Updates — Feb 29, 2024 Risk: medium
  Vaxart, Inc. filed an 8-K on February 29, 2024, reporting events that occurred on February 27, 2024. The filing primarily concerns the departure of directors or
• Vaxart Files 8-K for Undisclosed Event on Feb 14, 2024 — Feb 15, 2024 Risk: low
  Vaxart, Inc. filed an 8-K Current Report with the SEC on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates "Other E
• Vaxart Faces Delisting Threat, Reports Listing Rule Non-Compliance — Jan 19, 2024
  Vaxart, Inc. filed an 8-K on January 19, 2024, to report a "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
• Vaxart Files 8-K on Material Agreement; Details Undisclosed — Jan 16, 2024
  Vaxart, Inc. filed an 8-K on January 16, 2024, indicating an "Entry into a Material Definitive Agreement" and "Other Events." While the filing confirms Vaxart's

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX